Clinical trials: Patients With Advanced Solid Tumors
Solid Tumors
Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors
To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies
- Trial name
- NCT01447225
- Testing
- MM-121, Carboplatin, Pemetrexed
- Where
- 5 sites in United States, France
- Volunteers
- 43 people
- Sponsor
- Merrimack Pharmaceuticals
Advanced Solid Cancer
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
The trial is divided into three periods. Dosing will be the first day of each cycle, 21 days per cycle. The first period is the day of first study drug delivery until the 21st day, that is, the first treatment cycle.
- Trial name
- NCT03884517
- Testing
- BAT8003
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Bio-Thera Solutions
Solid Tumor, Adult, Advanced Solid Tumors
IMX-110 in Patients With Advanced Solid Tumors
Phase 1 is an open-label, multi-center dose escalation/dose expansion study designed to assess the safety, tolerability and pharmacokinetics (PK) for the recommended phase 2 dose (RP2D) of IMX-110.
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumors, Pancreatic Cancer, Breast Cancer
- Trial name
- NCT03382340
- Testing
- Imx-110
- Where
- 2 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Immix Biopharma Australia Pty Ltd
Advanced Solid Tumor
Study of LTC004 Combine With Toripalimab in Patient With Solid Tumors Resistant to Immunotherapy
To evaluate the efficacy and safety of LTC004 in combination with Toripalimab in 10 patients with advanced solid tumors resistant to first-line immunotherapy, all eligible subjects will receive LTC004 on day 1 of Week 1 and day 1…
- Trial name
- NCT06490068
- Testing
- LTC004+Toripalimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumors, Lymphoma
Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer
This is a multi-center, Phase I study of a new investigational drug, VTX-2337, that may stimulate the immune system to help fight cancer.
- Trial name
- NCT00688415
- Testing
- VTX-2337
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Celgene
Neoplasms, Advanced Solid Tumor
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
The main objectives of this study are to determine the safety profile of briciclib, an experimental anti-cancer drug, as it is administered intravenously once weekly as escalating doses in adult patients with advanced cancer and…
- Trial name
- NCT02168725
- Testing
- briciclib
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Traws Pharma, Inc.
Squamous Cell Carcinoma of Head and Neck
A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer
The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.
- Trial name
- NCT04144517
- Testing
- Nemvaleukin Alfa, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mural Oncology, Inc
Advanced Malignant Solid Tumors
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Research in test tubes suggests that may affect cytochrome P450 2D6 (CYP2D6), an important enzyme that is responsible for eliminating many drugs that cancer patients need to take, including dextromethorphan.
- Trial name
- NCT00728468
- Testing
- PF-00299804
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Solid Tumors, Head and Neck Cancer
A Study of SYH2051 Monotherapy in Advanced Solid Tumors or in Combination With Radiotherapy in Locally Advanced Head and Neck Cancer
This is an open-label, multicenter, dose-escalation phase I study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor efficacy of SYH2051 in patients with advanced solid tumors or in combination with…
- Trial name
- NCT06011291
- Testing
- SYH2051 tablets, Intensity-Modulated Radiation Therapy (IMRT)
- Where
- China
- Volunteers
- 73 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery
This phase Ib/II trial studies the best dose of glembatumumab vedotin when giving together with nivolumab and ipilimumab in treating patients with solid tumor that has spread to other places in the body and cannot be removed by…
- Conditions
- Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative, GPNMB Positive, HER2/Neu Negative
- Trial name
- NCT03326258
- Testing
- Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Cancers
Study of SC-102 in Patients With Advanced Solid Tumors
This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors
- Trial name
- NCT06710158
- Testing
- SC-102
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
Ovarian Sarcoma, Ovarian Stromal Cancer
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of temsirolimus, carboplatin, and paclitaxel in treating patients with advanced solid tumors.
- Conditions
- Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00408655
- Testing
- paclitaxel, carboplatin, temsirolimus
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Cancer, Non Small Cell Lung Cancer
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies.
- Conditions
- Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer
- Trial name
- NCT03917043
- Testing
- APG-2449
- Where
- 9 sites in China
- Volunteers
- 165 people
- Sponsor
- Ascentage Pharma Group Inc.
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers
This phase I trial studies how well CBX-12 works in treating patients with solid tumors that have spread from where they first started (primary site) to started to nearby tissue, lymph nodes, or distant parts of the body…
- Trial name
- NCT05691517
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Tumor
To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors
This is a Phase I open, multi-center, first-in-human study evaluating JSKN016 in subjects with advanced metastatic solid tumors, divided into dose escalation and dose extension.
- Trial name
- NCT06592417
- Testing
- JSKN016 injection
- Where
- 2 sites in China
- Volunteers
- 140 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumors
Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors
This study is designed to determine if treatment with HRS-1167 alone is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.
- Trial name
- NCT05473624
- Testing
- HRS-1167
- Where
- 20 sites in China
- Volunteers
- 153 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
This is a phase 1, open-label, multicenter dose-escalation study to determine the RP2D of CI 8993 for administration to patients with relapsed/refractory solid tumors by evaluating the safety and tolerability and characterizing…
- Trial name
- NCT04475523
- Testing
- CI-8993
- Where
- 6 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- Curis, Inc.
Breast Cancer, Colorectal Cancer
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00622674
- Testing
- cetuximab, bortezomib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Small Intestine Cancer
Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00005639
- Testing
- Azacitidine Injection, sodium phenylbutyrate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.